BioMarin Pharmaceuticals, Inc. (BMRN)

Company Description

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse(TM) (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include BMN-110 (N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which successfully completed Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers, and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

COMPANY ADDRESS
105 Digital Drive
Novato, CA 94949
United States

COMPANY PHONE
415-506-6700

COMPANY WEBSITE



Get BioInvest's perspective on BioMarin's CEO


Latest Company News

These stock's might change the kismet of Investors: BioMarin Pharmaceutical ... StockNewsJournal - 2 hours ago BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) market capitalization at present is $16.60B at the rate of $93.47 a share. The firm's price-to-sales ratio was noted 14.00 in contrast with an overall industry average of 3.70. Are Technical Indicators Looking Better For BioMarin Pharmaceutical Inc. (BMRN ... - Post Analyst Biomarin Pharmaceutical Inc (NASDAQ:BMRN) Institutional Investor Sentiment Trend - Weekly Register [...]
Tue, Jun 27, 2017 7:52:00 PM, Continue reading at the source
Investors Are Circling BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), What Do ... Stock Talker - 12 hours ago The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share repurchases and debt reduction. QI Valuation Update on BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) - Ozark Times [...]
Tue, Jun 27, 2017 9:33:00 AM, Continue reading at the source
Trading Options During Earnings in BioMarin Pharmaceutical Inc CML News - Jun 23, 2017 We're going to examine buying and selling out of the money strangles in BioMarin Pharmaceutical Inc and find out once and for all what the winning trades have been during earnings releases. [...]
Fri, Jun 23, 2017 2:37:00 PM, Continue reading at the source
The Markets Are Undervaluing these stock's: BioMarin Pharmaceutical Inc. (BMRN ... StockNewsJournal - Jun 23, 2017 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) market capitalization at present is $17.31B at the rate of $97.06 a share. The firm's price-to-sales ratio was noted 14.57 in contrast with an overall industry average of 3.69. BioMarin Pharmaceutical Inc. (BMRN) Moves Higher on Volume Spike for June 21 - Equities.com Hot Stock Assessment: BioMarin Pharmaceutical Inc. (BMRN) - StandardOracle [...]
Fri, Jun 23, 2017 1:07:00 PM, Continue reading at the source
The Technical Chart BioMarin Pharmaceutical Inc. (BMRN) Is Speaking Volumes NY Stock News - Jun 22, 2017 The technicals for BioMarin Pharmaceutical Inc. (BMRN) has spoken via its technical chart and the message is loud and clear. [...]
Thu, Jun 22, 2017 6:00:00 PM, Continue reading at the source
BioMarin (BMRN) in Focus: Stock Moves 7% Higher Zacks.com - Jun 22, 2017 BioMarin Pharmaceutical Inc. (BMRN - Free Report) was a big mover last session, as the company saw its shares rise 7% on the day. [...]
Thu, Jun 22, 2017 11:37:00 AM, Continue reading at the source
Stock Alert: BioMarin Pharmaceutical Inc Realized Volatility Hits A Plunging Low CML News - Jun 17, 2017 Before we cover the full analysis we make a quick alert here that BioMarin Pharmaceutical Inc (NASDAQ:BMRN) has seen its stock price move at an extreme low level. BioMarin Pharmaceutical Inc. (BMRN) Moves Lower on Volume Spike for June 16 - Equities.com Investor's Watch List : Shire PLC (ADR) (NASDAQ:SHPG), BioMarin Pharmaceutical ... - Stocks In Focus (press release) [...]
Sat, Jun 17, 2017 1:18:00 AM, Continue reading at the source
BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound? Zacks.com - Jun 8, 2017 A month has gone by since the last earnings report for BioMarin Pharmaceutical Inc. (BMRN - Free Report) . Shares have lost nearly 8% in that time frame, underperforming the market. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading Down – Insiders Are Selling - Highlight Press Insider Selling: BioMarin Pharmaceutical Inc. (BMRN) EVP Sells 2500 Shares of ... - The Cerbat Gem [...]
Thu, Jun 08, 2017 12:45:00 PM, Continue reading at the source
European Commission Approves Brineura™ (cerliponase alfa), the First ... PR Newswire (press release) - Jun 1, 2017 SAN RAFAEL, Calif., June 1, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the European Commission (EC) has granted marketing authorization for Brineura™ (cerliponase alfa), the first treatment approved in the ... BioMarin's (BMRN) Brineura Approved by European Commission - Zacks.com BioMarin's Brineura OK'd in EU - Seeking Alpha [...]
Thu, Jun 01, 2017 12:33:00 PM, Continue reading at the source
BioMarin to Attend Upcoming Investor Conference PR Newswire (press release) - May 31, 2017 SAN RAFAEL, Calif., May 31, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will participate in the Goldman Sachs 38th Annual Global ... [...]
Wed, May 31, 2017 10:03:00 AM, Continue reading at the source